Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea

BACKGROUND: Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is active against most strains of Neisseria gonorrhoeae (N. gonorrhoeae). Phase II data suggested higher exposures were needed for efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Scangarella-Oman, Nicole E, Hossain, Mohammad, Perry, Caroline R, Tiffany, Courtney, Powell, Marcy, Swift, Brandon, Dumont, Etienne F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887395/
https://www.ncbi.nlm.nih.gov/pubmed/36411033
http://dx.doi.org/10.1136/sextrans-2022-055518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887395/
https://www.ncbi.nlm.nih.gov/pubmed/36411033
http://dx.doi.org/10.1136/sextrans-2022-055518

Ejemplares similares